Clinical benefits of resistance assay for HIV-specific protease inhibitors: when to check and in whom?
Aizawa
S
S
Gatanaga
H
H
Ida
S
S
Sakai
A
A
Tanaka
M
M
Takahashi
Y
Y
Hirabayashi
Y
Y
Oka
S
S
D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004352:Drug Resistance, Microbial / Q000235:genetics; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology*; D016333:HIV Protease / Q000235:genetics*; D017320:HIV Protease Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics; D006801:Humans; D009154:Mutation; D012367:RNA, Viral / Q000097:blood; D012189:Retrospective Studies; D013997:Time Factors; D019562:Viral Load
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D016333:HIV Protease